title: Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
abstract: BACKGROUND
  Tumour necrosis factor (TNF) antagonists have proved effective as treatment against rheumatoid arthritis (RA), but the unresolved issue of whether the use of anti-TNF therapy increases the already elevated risk of lymphoma in RA remains a concern.
  
  
  METHODS
  Using the Swedish Biologics Register (ARTIS), the Swedish Cancer Register, pre-existing RA cohorts and cross-linkage with other national health and census registers, a national RA cohort (n = 67,743) was assembled and patients who started anti-TNF therapy between 1998 and July 2006 (n = 6604) were identified. A general population comparator (n = 471,024) was also assembled and the incidence of lymphomas from 1999 to 31 December 2006 was assessed and compared in these individuals.
  
  
  RESULTS
  Among the 6604 anti-TNF-treated RA patients, 26 malignant lymphomas were observed during 26,981 person-years of follow-up, which corresponded to a relative risk (RR) of 1.35 (95% CI 0.82 to 2.11) versus anti-TNF-naive RA patients (336 lymphomas during 365,026 person-years) and 2.72 (95% CI 1.82 to 4.08) versus the general population comparator (1568 lymphomas during 3,355,849 person-years). RA patients starting anti-TNF therapy in 1998-2001 accounted for the entire increase in lymphoma risk versus the two comparators. By contrast, RR did not vary significantly by time since start of first treatment or with the accumulated duration of treatment, nor with the type of anti-TNF agent.
  
  
  CONCLUSIONS
  Overall and as used in routine care against RA, TNF antagonists are not associated with any major further increase in the already elevated lymphoma occurrence in RA. Changes in the selection of patients for treatment may influence the observed risk.
authors.affiliation: Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden. johan.askling@ki.se
authors.forename: J
authors.initials: J
authors.lastname: Askling
authors.forename: E
authors.initials: E
authors.lastname: Baecklund
authors.forename: F
authors.initials: F
authors.lastname: Granath
authors.forename: P
authors.initials: P
authors.lastname: Geborek
authors.forename: M
authors.initials: M
authors.lastname: Fored
authors.forename: C
authors.initials: C
authors.lastname: Backlin
authors.forename: L
authors.initials: L
authors.lastname: Bertilsson
authors.forename: L
authors.initials: L
authors.lastname: Cöster
authors.forename: L T
authors.initials: LT
authors.lastname: Jacobsson
authors.forename: S
authors.initials: S
authors.lastname: Lindblad
authors.forename: J
authors.initials: J
authors.lastname: Lysholm
authors.forename: S
authors.initials: S
authors.lastname: Rantapää-Dahlqvist
authors.forename: T
authors.initials: T
authors.lastname: Saxne
authors.forename: R
authors.initials: R
authors.lastname: van Vollenhoven
authors.forename: L
authors.initials: L
authors.lastname: Klareskog
authors.forename: N
authors.initials: N
authors.lastname: Feltelius
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology; D004334:Drug Administration Schedule; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D013548:Sweden / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha